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Abstract
Consensus molecular subtyping is an RNA expression-based classification system for colorectal cancer (CRC).
Genomic alterations accumulate during CRC pathogenesis, including the premalignant adenoma stage, leading to
changes in RNA expression. Only a minority of adenomas progress to malignancies, a transition that is associated
with specific DNA copy number aberrations or microsatellite instability (MSI). We aimed to investigate whether
colorectal adenomas can already be stratified into consensus molecular subtype (CMS) classes, and whether specific
CMS classes are related to the presence of specific DNA copy number aberrations associated with progression to
malignancy. RNA sequencing was performed on 62 adenomas and 59 CRCs. MSI status was determined with
polymerase chain reaction-based methodology. DNA copy number was assessed by low-coverage DNA sequencing
(n= 30) or array-comparative genomic hybridisation (n= 32). Adenomas were classified into CMS classes together
with CRCs from the study cohort and from The Cancer Genome Atlas (n= 556), by use of the established CMS
classifier. As a result, 54 of 62 (87%) adenomas were classified according to the CMS. The CMS3 ‘metabolic
subtype’, which was least common among CRCs, was most prevalent among adenomas (n= 45; 73%). One of the
two adenomas showing MSI was classified as CMS1 (2%), the ‘MSI immune’ subtype. Eight adenomas (13%) were
classified as the ‘canonical’ CMS2. No adenomas were classified as the ‘mesenchymal’ CMS4, consistent with the
fact that adenomas lack invasion-associated stroma. The distribution of the CMS classes among adenomas was
confirmed in an independent series. CMS3 was enriched with adenomas at low risk of progressing to CRC, whereas
relatively more high-risk adenomas were observed in CMS2. We conclude that adenomas can be stratified into
the CMS classes. Considering that CMS1 and CMS2 expression signatures may mark adenomas at increased risk of
progression, the distribution of the CMS classes among adenomas is consistent with the proportion of adenomas
expected to progress to CRC.
© 2018 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain
and Ireland.
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Introduction
Colorectal cancer (CRC) is heterogeneous in its molecu-
lar characteristics and its treatment response. Stratifying
CRC patients into biologically and clinically distinct
subtypes, based on gene expression profiles, has been
performed in many studies, with the common aim of
improving clinical precision [1–7]. Recently, a large
effort was made by the CRC Subtyping Consortium to
reconcile the differences between the multiple exist-
ing classifications and to derive consensus molecular
subtypes (CMSs) of CRC [8]. A consensus RNA
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expression-based classifier was produced that classifies
CRCs into four CMS groups. CMS1 includes ∼14% of
CRCs, and is associated with microsatellite instability
(MSI), BRAF mutation, promoter hypermethylation,
and immune infiltration. Chromosomal instability
(CIN), the most common type of genomic instability
in CRC, is a feature characteristic of CMS2–CMS4.
CMS2 is the most prevalent CRC subtype (37%) and
shows the hallmarks of canonical CRC carcinogenesis,
including activation of the Wnt and Myc pathways.
Approximately 13% of CRCs are in CMS3, charac-
terised by dysregulated metabolism andKRASmutation.
Finally, CMS4 (23%) is described as a mesenchymal,
stroma-rich group, associated with poor prognosis [8].
Most CRCs progress from normal epithelium,
through a benign precursor adenoma, by accumulating
genetic alterations in oncogenes and tumour suppressor
genes [9]. However, adenomas are much commoner in
the large intestine than cancers, and it is estimated that
only 5% eventually progress to cancer [10]. Although
it is evident that CMS signatures can be discerned at
the CRC stage, the question remains of whether this
would already be possible at the adenoma stage, and, if
so, how the distribution of CMS classes would compare
with that of CRCs.
A further question is whether adenomas with a high
risk of progressing to cancer would differ in their CMS
pattern from adenomas with a low risk of progression.
In general, the progression of dysplastic epithelial pre-
malignant lesions such as colorectal adenomas is associ-
ated with the acquisition of genomic instability. Often,
this concerns aneuploidy or CIN, which marks ∼85%
of CRC cases [11]. CIN has been studied in CRC and
its precursor lesions to identify non-random chromo-
somal aberrations and potential CRC driver events. In
multiple studies, a distinct pattern has been observed
in colorectal lesions with CIN, which has been shown
to play a major role in adenoma-to-carcinoma pro-
gression [12–21]. Seven copy number aberrations have
been identified as colorectal cancer-associated events
(CAEs): gains of chromosomal arms 8q, 13q, and 20q,
and losses of 8p, 15q, 17p, and 18q [12]. With an
accuracy of 78%, adenomas with at least two of the
seven CAEs can be identified as being at a high risk
of progressing to malignancy; these are referred to as
‘high-risk adenomas’ [12]. Integration of these DNA
copy number aberrations and RNA expression data led
to the identification of putative oncogenes located in
the amplified regions [22,23]. Functional studies of
candidate oncogenes from the 20q region indicated
that AURKA and TPX2 promote 20q amplicon-driven
adenoma-to-carcinoma progression [16]. This means
that the non-random DNA copy number aberrations
do, in fact, influence biological processes within cells,
through which they facilitate colorectal tumourigenesis.
The fact that these aberrations are present in some of
the adenomas shows that the signal of malignant trans-
formation can already be detected at a molecular level
at the adenoma stage. This implies that gene expression
profiles of colorectal adenomas may also carry informa-
tion on the future CMS.
The present study therefore aimed to investigate
whether the differentiation of colorectal epithelial neo-
plasia into CMS classes can already be recognised at
the adenoma stage, and whether specific CMS classes
are associated with the absence or presence of specific
DNA copy number aberrations in colorectal adenomas
that reflect a high risk of progressing to cancer.
Materials and methods
Sample collection
A total of 62 snap-frozen advanced adenomas and
59 CRCs were collected from two independent sam-
ple collections: Series 1 and Series 2 (described in
supplementary material, Supplementary materials and
methods). Clinical information is shown in Table 1.
The collection, storage and use of tissue and patient
data were performed in compliance with the Code
for Proper Secondary Use of Human Tissue in the
Netherlands [24].
DNA copy number analysis
For Series 1, copy number analysis by low-coverage
whole genome sequencing was performed (supplemen-
tary material, Supplementary materials and methods and
Table S1). Gains and losses of whole chromosomal arms
were used for the identification of high-risk adenomas.
Table 1. Characteristics of sample Series 1 and Series 2 collected
for this study
Number of samples
Characteristics Series 1 Series 2 Total
Lesion Adenoma 30 32 62
Histological type Tubular 6 13 19
Tubulovillous 20 16 36
Villous 4 3 7
Dysplasia High grade 10 8 18
Low grade 20 24 44
Risk of progression High 9 4 13
Low 17 22 39
No information 2 6 8
Microsatellite status MSS 28 32 60
MSI 2 0 2
Lesion Carcinoma 30 29 59
Differentiation grade Less/Not 4 2 6
Well differentiated/
moderately
differentiated
25 27 52
No information 1 0 1
Stage I 7 9 16
II 13 10 23
III 6 9 15
IV 3 1 4
I or III 1 0 1
Microsatellite status MSS 24 23 47
MSI 6 6 12
MSS, microsatellite-stable.
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Samples were considered to have undetermined risk
when the copy number aberrations were present but
did not reach the probability cut-off of 0.5 (n= 2). For
Series 2, DNA copy number data for 28 adenomas were
obtained from the array-comparative genomic hybridis-
ation (arrayCGH) analysis in an earlier study [22]. Sam-
ples were considered to have undetermined risk if the
arrayCGH data were unavailable (n= 4) or only a minor
part of the chromosomal arm was gained or lost (n= 2).
For both series, adenomas with at least two of seven
CAEs were labelled as high-risk [12].
MSI assay
Adenoma and carcinoma samples from both series
were analysed for MSI with the MSI Multiplex Sys-
tem Version 1.2 (Promega, Madison, WI, USA; cat.
no. MD1641) according to standard procedures, as
described previously [25].
RNA sequencing (RNA-seq) and data preprocessing
Both series were subjected to RNA-seq and data prepro-
cessing separately. Expression matrices were obtained
for each series (supplementary material, Supplementary
materials and methods and Table S1).
Batch effect removal with respect to The Cancer
Genome Atlas (TCGA) CRC data
TCGA data served as a reference for performance of
the analysis in the present study [15]. Expression val-
ues of 556 TCGA samples used in the original CMS
classification were used for RNA-seq data normalisation
and CMS classification (supplementary material, Sup-
plementary materials and methods).
The batch effect was removed with M-Combat [26],
separately for Series 1 and Series 2. In both cases, the
TCGA dataset served as the reference, and Series 1
or Series 2 served as the normalised batch (Figure 1).
Adenomas and cancers were kept together during the
normalisation to avoid removal of the ‘lesion-based’
variance. TCGA data as the gold-standard reference
dataset remained unchanged. All three datasets (Series
1, Series 2, and TCGA) were merged, and Series 1 and
Series 2 formed the study dataset. Batch effect removal
was evaluated by use of amultidimensional scaling algo-
rithm on the Euclidian distance between the expression
profiles of the samples. Evaluation of the preservation of
the difference between adenomas and carcinomas was
performed by the use of hierarchical clustering with
complete linkage on the log2-transformed RPKMs of the
top 30 and the top 1000 variable genes.
CMS classification
Ensembl IDs were translated to Entrez IDs with the
biomaRt Bioconductor package [27]. The random forest
CMS classifier [8] was applied on the merged dataset,
including TCGA dataset, Series 1, and Series 2, and a
CMS class was assigned when the posterior probability
of a sample belonging to a subtype was ≥0.5. To
obtain the original CMS labels for TCGA samples,
the random forest CMS classifier was also applied to
the whole CMS dataset downloaded from the CRC
Subtyping Consortium Synapse website [8,28]. CMS
labels for TCGA samples were extracted. To evaluate
the results of the random forest CMS classifier, the
single sample predictor (SSP) classification method [8]
was applied to the adenomas from Series 1 and Series
2 before normalisation to the TCGA dataset. A CMS
class was assigned according to the default settings
(minCor= 0.15, minDelta= 0.06).
Validation set
To validate the results in an independent series of ade-
nomas measured with a different platform, expression
data from the Affymetrix Human Genome U133 Plus
2.0 Array of 45 colorectal adenomas and 36 CRCs
(GSE20916) were downloaded from the Gene Expres-
sion Omnibus. This validation set will be referred
as ‘Series 3’ [29]. The reference dataset chosen was
the largest series of CRCs measured with the same
methodology and used in the original CMS classifica-
tion (GSE39582) [3,8]. See supplementary material,
Supplementary materials and methods for details of
data analysis and the CMS classification of Series 3.
Statistical analysis
The multinomial exact test was used to perform a
goodness-of-fit test for the distributions of CMS classes
in the adenomas in comparison with cancers from
the study dataset, adenomas from the validation set,
and cancers from the original CMS publication [8].
Contingency tables including adenomas classified as
CMS2 and CMS3 were analysed; CMS1 and CMS4
were excluded because of the limited number of cases.
Associations analysed were clinical features, risk of
progression or occurrence of each of the seven CAEs
separately. A relationship was considered to be sig-
nificant if the P value was ≤0.05 (Fisher’s exact test).
Additionally, associations between CMS classes in
CRCs and clinical features were analysed.
Gene set enrichment analysis (GSEA)
Prior to GSEA [30], an expression matrix after normal-
isation was extracted for CMS2 and CMS3 adenomas.
Exponentiation with base 2 was applied, and values
were rounded to integers to create count data. Differ-
ential gene expression analysis was performed with the
Bioconductor package DESeq2 [31], and genes were
sorted on the basis of log2 fold change, whereby genes
upregulated in CMS2 adenomas were at the top of
the list. (Fold change is defined as the ratio of test to
reference expression level.) The log2 fold change-based
ranked list was submitted to GSEA [30], and the col-
lection of hallmark gene sets from Molecular Signature
Database v6.0 was used [32]. Significant gene sets were
extracted on the basis of a false discovery rate (FDR)
threshold of ≤0.2. For the comparison of stroma and
invasion signatures between adenomas and cancers,
© 2018 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2018
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Figure 1. Overview of the data analysis approach. Both Series 1 and Series 2 were normalised separately to the TCGA CRC dataset via a batch
effect removal method [27]. After normalisation, all three datasets were merged together. Series 1 and Series 2 form the ‘study dataset’.
CMS classification was applied to the merged dataset. The classes were obtained with the CMS random forest classifier, and assigned when
the posterior probability of belonging to a CMS class was ≥0.5. Results of the classification were extracted for the CRCs and the adenomas
from the study dataset. The pie charts represent the distribution of CMS classes for CRCs (left) and adenomas (right) for the study dataset.
the ESTIMATE algorithm [33] was used, as well as
single-sample GSEA with the GSVA Bioconductor
package [34], with the ‘invasive front’ and ‘central
tumour’ signatures [35].
Results
CMS classification of the cancers and the adenomas
An overview of the data analysis is shown in Figure 1.
Series 1, Series 2 and the TCGA dataset originated
from different experiments, representing three separate
batches that needed to be normalised (supplementary
material, Figure S1A). To avoid a change in the origi-
nal TCGA classification, the TCGA dataset remained
unchanged and was used as a gold-standard reference
for batch effect removal. Both Series 1 and Series 2
were successfully normalised to the TCGA dataset
(supplementary material, Figure S1B). Hierarchical
clustering based on expression values of the top 30 and
top 1000 variable genes before and after batch effect
removal showed that the normalisation did not remove
© 2018 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2018
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Figure 2. Hierarchical clustering based on gene expression profiles of the top 30 most variable genes. (A) Heatmap of all three datasets
before batch effect removal. The batches corresponding to the TCGA dataset, Series 1 and Series 2 can be distinguished in the heatmap.
(B) Heatmap before batch correction of the Series 1 and Series 2 study datasets only. Within the two batches, one can distinguish clusters
enriched with adenomas and clusters enriched with cancers. (C) Heatmap of all three datasets after batch effect removal. Samples from
the three experiments do not cluster together. (D) Heatmap of the Series 1 and Series 2 study datasets after batch effect removal. Clusters
enriched with adenomas or cancers can still be distinguished, meaning that batch effect correction did not remove the variability between
different lesions. The legend corresponds to all of the heatmaps in this figure.
the differences between the adenomas and the cancers,
as the lesions could still be distinguished on the basis of
their expression profiles (Figure 2; supplementary mate-
rial, Figure S2). The variability between cancers and
adenomas was thus preserved after batch effect removal.
On the basis of two tissue datasets, Series 1 and
Series 2, we collected a cohort of 62 adenomas and
59 CRCs, referred to as the study dataset. To ensure
proper classification of the adenomas, which constitute a
different entity from CRCs, the CMS classification was
applied to a merged dataset with carcinomas from the
present study (n= 59) and TCGA data (n= 556); see
Figure 1 for an overview of the data analysis approach.
To evaluate whether the data analysis approach had an
impact on the classification, the CMS labels obtained
in this study for TCGA samples were compared with
their original CMS labels [8]. The CMS labels of TCGA
samples were reassigned in this study with an accuracy
of 97%, corresponding to the previously reported overall
accuracy of the random forest CMS classifier of 96%
(supplementary material, Table S2) [8].
The CMS classification results of the study dataset
were extracted. In total, 48 of 59 cancers were classified
with a posterior probability of ≥0.5. Of these, seven
were classified as CMS1, 15 as CMS2, two as CMS3,
and 24 as CMS4 (Figure 1; Table 2; supplementary
material, Table S3). Hence, the CMS4 mesenchymal
subtype was the most prevalent in this dataset. Of the
12 samples of CRC with MSI, four were classified as
CMS1, four were classified as CMS4, one was classified
as CMS3, and three were not classified. Statistically
significant associations of CMS classes with MSI status
(p= 0.004) and with differentiation grade (p= 0.006)
were observed, but no association with stage was iden-
tified (p= 0.235; see supplementary material, Table S4,
for MSI status and association analysis).
CMS subtype signatures were indeed expressed in
the adenomas, and 54 of 62 samples were success-
fully classified with a probability threshold of ≥0.5. The
© 2018 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2018
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Table 2. Distribution of the CMS classes in cancers and adenomas from the study dataset and the validation set
CMS1, n (%) CMS2, n (%) CMS3, n (%) CMS4, n (%) Non-consensus, n (%)
Study dataset (Series 1 and Series 2)
Cancers 7 (12) 15 (25) 2 (3) 24 (41) 11 (19)
Adenomas 1 (2) 8 (13) 45 (73) 0 (0) 8 (13)
Validation set (Series 3)
Cancers 5 (14) 7 (19) 1 (3) 18 (50) 5 (14)
Adenomas 1 (2) 5 (11) 28 (62) 0 (0) 11 (24)
vast majority of the adenomas, i.e. 45 samples (73%),
were assigned to CMS3. Additionally, eight adenomas
(13%) were subtyped as CMS2, representing the canon-
ical CRC carcinogenesis. Only a single adenoma was
classified as CMS1, being one of the two MSI adeno-
mas identified in the whole dataset. No adenomas were
subtyped as CMS4 (Table 2; supplementary material,
Table S5). The distribution of CMS classes in the ade-
nomas differed significantly from that in the CRCs from
the study dataset (p< 2.2× 10–16) and CRCs from the
original CMS publication (p< 2.2× 10–16) [8].
CMS classification of adenomas, risk of progression,
and biological characterisation
Adenomas from the study dataset were called high risk
on the basis of the presence of at least two of seven
specific DNA copy number aberrations: 8q, 13q and 20q
gains, and 8p, 15q, 17p and 18q losses [12]. Adenomas
with MSI were excluded, because a different genome
instability process (i.e. not CIN) is involved. In total,
13 adenomas were called high risk and 39 were called
low risk (Table 1; supplementarymaterial, Table S6). No
final calls could be made for the remaining eight.
Adenomas classified as CMS2 (n= 8) and CMS3
(n= 45) were the most prevalent; there were no CMS4
adenomas, and there was one adenoma classified as
CMS1. Therefore, only differences between CMS2
and CMS3 adenomas were examined in terms of risk
of progression, cancer-specific DNA copy number
aberrations, clinical characteristics, and biological
processes specific for each group. Examination of
associations between CMS class and risk of progression
revealed that CMS2 was significantly associated with
high-risk adenomas and CMS3 with low-risk adeno-
mas (p= 0.025; Figure 3). When each of the seven
CAEs were examined, gain of 20q and loss of 18q
were significantly associated with CMS2 (p= 0.004
and p= 0.031, respectively). No statistically significant
associations were observed between CMS class and
histological type (p= 0.362) and grade of dysplasia
(p= 0.389), or between high-risk genotypic features
and histological type (p= 0.77) and grade of dysplasia
(p= 0.079; supplementary material, Table S7).
To explore associations of CMS2 and CMS3
adenomas with well-defined biological processes,
we performed GSEA on the hallmark gene sets
(Table 3) [30]. As expected, the gene sets enriched
in CMS2 adenomas were involved in cell cycle and
proliferation, including genes that are targets of
Figure 3. Distribution of CMS classes among adenomas at high risk
and adenomas at low risk of progressing to cancer. (A) Distribution
of CMS classes among 13 high-risk adenomas. (B) Distribution
of CMS classes among 39 low-risk adenomas. No high-risk and
low-risk adenomas were classified as CMS1 or CMS4.
E2F transcription factors, genes involved in G2/M
checkpoint, mitotic spindle assembly, the phospho-
inositide 3-kinase (PI3K)–AKT–mammalian target of
rapamycin (mTOR) pathway, and the Wnt–β-catenin
signalling pathway, or genes regulated by MYC. These
results are in line with the biological characterisation
of CMS2 CRCs, which are known to be enriched with
proliferation and cell cycle pathways [8]. Another
gene set enriched in the CMS2 adenoma group was
apical junction, this process also relates to increased
proliferation. Additionally, CMS2 adenomas expressed
genes involved in epithelial–mesenchymal transition,
the transforming growth factor (TGF)-β signalling
pathway, and the development of muscles, which are
processes typically assigned to CMS4 CRCs, and
genes involved in the immune response (coagulation),
which are characteristic of CMS1 CRCs. Consider-
ing that the enrichment analysis in the original CMS
CRC characterisation was performed by comparing
each CMS class with the other three CMS classes,
the fact CMS1-specific and CMS4-specific processes
arose in the CMS2 versus CMS3 comparison does not
represent a contadictory result, as a different analysis
was performed in this study. On the other hand, the
majority of gene sets enriched in CMS3 adenomas
were metabolism-associated, including those involved
in haem, fatty acid and sugar metabolism, which is
in line with the original characterisation of the CMS3
‘metabolic’ CRC subtype.
To examine the differences between CMS2 andCMS3
adenomas in the context of CMS classes in CRC, ‘stro-
mal scores’ and ‘immune scores’ from the ESTIMATE
algorithm [33] and previously published ‘invasive front’
© 2018 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2018
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Table 3. Gene sets enriched in CMS2 and CMS3 adenomas
Gene set Process category Size Members in signal Normalised enrichment score P value FDR
Gene sets enriched in CMS2 adenomas in comparison with CMS3 adenomas
G2M checkpoint Proliferation 183 100 2.00 <0.001 <0.01
E2F targets Proliferation 183 105 1.77 <0.001 0.01
MYC targets V2 Proliferation 57 78 1.57 0.005 0.02
Mitotic spindle Proliferation 168 28 1.58 0.001 0.02
Epithelial–mesenchymal transition Development 136 51 1.74 <0.001 0.01
Myogenesis Development 103 42 1.67 0.001 0.01
PI3K–AKT–mTOR signalling Signalling 85 38 1.62 0.004 0.01
Wnt–β-catenin signalling Signalling 33 13 1.61 0.005 0.02
TGF-β signalling Signalling 50 14 1.59 0.007 0.02
Coagulation Immune 85 35 1.64 0.002 0.01
Apical junction Cellular component 123 47 1.49 0.006 0.04
Gene sets enriched in CMS3 adenomas in comparison with CMS2 adenomas
Protein secretion Pathway 90 35 –1.78 <0.001 0.03
Glycolysis Metabolic 169 45 –1.52 <0.001 0.08
Oxidative phosphorylation Metabolic 194 85 –1.39 <0.001 0.13
Fatty acid metabolism Metabolic 132 39 –1.35 0.017 0.13
Haem metabolism Metabolic 144 33 –1.27 0.020 0.15
Oestrogen response late Signalling 152 32 –1.30 0.020 0.15
Gene sets were grouped in process categories according to the original hallmark gene set grouping [32]. Size indicates number of genes in the gene set; members
in signal indicates how many genes from the gene set contributed to the enrichment score. The statistical values, normalised enrichment score, P values and FDR
were calculated with GSEA [30]. Gene sets enriched in CMS2 adenomas have positive enrichment scores, and gene sets enriched in CMS3 adenomas have negative
enrichment scores.
and ‘central tumour’ signature enrichments were cal-
culated [35] (supplementary material, Figure S5). As
expected, ‘stromal score’ and tumour ‘invasive front’
signatures showed a high level of enrichment in CMS4
CRCs as compared with adenomas and other CMS CRC
classes. The ‘immune score’ was enriched in CMS1 can-
cers as compared with CMS2–3 lesions, whereas the
‘central tumour’ signature showed similar results for all
groups.
Validation in the independent series
Validation of the CMS classification results in col-
orectal adenomas was performed in an independent
series – Series 3 (GSE20916) [29]. Series 3 consists
of colorectal adenomas (n= 45) and cancers (n= 36)
measured on the Affymetrix array. To perform a similar
analysis as that used for the study dataset, CRCs from
the GSE39582 dataset (n= 566) were chosen as the ref-
erence dataset for batch effect removal, normalisation,
and CMS classification [3]. This reference dataset was
the largest CRC series measured on the same platform
as Series 3 and used in the original CMS classification
publication [8]. CMS classes were extracted for CRCs
and adenomas from Series 3 (Table 2; supplementary
material, Table S8). CMS classification of colorectal
adenomas in Series 3 confirmed the results obtained
with the study dataset, with most adenomas being
labelled as CMS3 (n= 28, 62%), none as CMS4, and
a small number as CMS1 (n= 1, 2%) or CMS2 (n= 2,
11%) (Table 2; supplementary material, Table S8). In
Series 3, the distribution of the CMS classes among
adenomas differed significantly from that of the cancers
from the same series (p< 2.2× 10–16). No significant
differences between the distribution of CMS classes
among adenomas from the study dataset and those from
the validation set were observed (p= 0.13).
Discussion
CMS classification constitutes an established consensus
gene expression-based subtyping of CRC. We set out
to determine whether this molecular classification is
already present at the adenoma stage. Classification
of adenomas according to CMS was achieved for 54
of 62 adenomas, in a group-wise analysis together
with 59 CRCs from the study dataset and 556 TCGA
CRC samples [15,36]. The results were validated in the
independent series, in which 34 of 45 adenomas where
classified with the same method; group-wise analysis
including 36 CRCs from the same series and 566 CRCs
from the reference dataset [3,29].
The distribution of CMS classes in adenomas differed
significantly from that in CRCs, in both the study dataset
and the validation dataset. The vast majority (73% and
62% for the study and validation sets, respectively) of
adenomas were classified as the ‘metabolic’ CMS3 type,
which was the least frequent CMS class among CRCs
from the study dataset (3%). Multiple gene expression
profiling studies of colorectal adenomas and CRCs have
shown upregulated metabolism in adenomas. In partic-
ular, pathway analysis of genes overexpressed in ade-
nomas in comparison with cancers revealed the same
pathways that were dysregulated in CMS3, including
fatty acid, amino acid and sugar metabolism [8,37,38].
It is evident that metabolic deregulation already occurs
at the adenoma stage. In this study, GSEA comparing
CMS2 and CMS3 adenomas confirmed enrichment of
metabolic pathways in CMS3 adenomas. The results of
this study imply that CMS3 is more representative of
the adenoma than of the carcinoma stage. From the per-
spective of which adenomas have a risk of progressing
to cancer, CMS3may well represent low-risk adenomas,
which was confirmed by the enrichment of low-risk ade-
nomas in this class as defined by the presence of DNA
© 2018 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2018
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copy number aberrations. As most adenomas never
progress to cancer (95%), the observed frequency of
CMS3 adenomas is consistent with this hypothesis.
Conversely, none of the adenomas from either the
study dataset or the validation dataset were classified
as the stroma-rich poor-prognosis CMS4 class. A
process inherent to invasion and thus colorectal
adenoma-to-carcinoma progression is activation of
tumour stroma [21,39]. In fact, the tumour stroma rep-
resents an inflammatory response to foreign intruders,
as well as being a scaffold for invading tumour cells.
Mucosa of colorectal adenomas contains dysplastic
epithelium as well as stroma (the lamina propria). In
adenomas, this resembles the lamina propria of normal
mucosa, being a framework of loose connective tissue,
capillaries, myofibroblasts, and immune cells, and is
quite different from the reactive stroma of cancers,
which is the most prominent in CMS4 CRC. The lack
of the mesenchymal subtype has also been observed for
colorectal organoids, which are purely epithelial, and
for patient-derived xenografts, in which the stroma is of
mouse origin [40,41]. Multiple studies have shown that
the CMS4 signature is mostly driven by stroma rather
than epithelial cancer cells [41–43]. As the typical
desmoplastic cancer stroma is, by definition, absent
in adenomas, it is no surprise that no adenomas were
classified as CMS4.
Regarding the CMS1 and CMS2 classes, the CMS
classifier subtyped one of the adenomas with MSI as
CMS1 and the second one as CMS3. MSI is rare in
colorectal adenomas, with a prevalence of 3% overall
[44], whereas approximately 15–20% of CRCs show
MSI [45]. The observations in the present study are
consistent with these data. When colorectal adenomas
acquire MSI, they are considered to progress rapidly,
leaving a small window of opportunity for them to be
detected, resulting in the low frequency of MSI in col-
orectal adenomas. Not all adenomas with MSI were
classified as CMS1, consistent with the observations
made on CRCs with MSI, a subset of which were also
classified as CMS3 [8]. Specific features that discrim-
inate CMS1 CRCs with MSI and CMS3 CRCs with
MSI have not been described yet. In the validation
set, one adenoma was classified as CMS1 as well, but
the MSI status of this adenoma is unknown. Eight of
the adenomas were classified as CMS2 in the study
dataset, and five in the validation set. From the per-
spective of adenoma-to-carcinoma progression, this is
particularly interesting, as CMS2 represents canonical
CRC carcinogenesis. Given that Wnt andMYC pathway
activation occurs mostly in the transition from normal
epithelium to adenoma, it may seem unexpected that
CMS2 is not the predominant class within adenomas
[46]. On the assumption that not the sequential order
but the accumulation of mutations causes tumour pro-
gression, there must be more alterations in these ade-
nomas to be classified as CMS2. Indeed, the enrich-
ment of high-risk adenomas within CMS2 suggests
that CMS2 adenomas might be closer to becoming
malignant than those classified as CMS3. Additionally,
the chromosomal gain of 20q and loss of 18q were
found to occur more often in CMS2 adenomas. Gain
of 20q is associated with a gene dosage effect of mul-
tiple genes [16], including AURKA and TPX2, which
play a role in the G2/M phase of the cell cycle [47].
This is consistent with the observed enrichment of the
G2/M checkpoint and mitotic spindle assembly gene
sets in CMS2 adenomas. Another characteristic spe-
cific for adenoma-to-carcinoma progression and the
CMS2 adenoma class is upregulation of pathways such
as the cell cycle and epithelial differentiation [21]. In
this study, GSEA confirmed that CMS2 adenomas have
increased expression of genes involved in prolifera-
tion, the cell cycle and even epithelial–mesenchymal
transition as compared with CMS3 adenomas. These
findings are in line with CMS2 CRC characterisation
as well as with the biological processes required for
adenoma-to-carcinoma progression. Our results suggest
that CMS2 adenomas, rather than CMS3 adenomas,
may represent lesions at risk of becoming malignant.
Owing to the lack of copy number information in
Series 3, the association between risk of progression
and CMS classification could not be further validated.
Nevertheless, this association should be further inves-
tigated. Adenomas, once detected during colonoscopy,
are completely removed, thereby interrupting their nat-
ural history in terms of either progressing to cancer or
not. Currently, adenoma-to-carcinoma progression can
only be studied in vitro by the use of, for example,
organoid models. Although this has been done by per-
turbing frequently mutated cancer genes with promi-
nent roles in CRC pathogenesis [48], relevant aspects
of adenoma-to-carcinoma progression, including CIN,
still remain to be incorporated in these model system
studies.
The CMS classification of cancers revealed a rela-
tively large number of CMS4 cases in the present series.
Taking into account the different sample sizes of the cur-
rent study and the original CMS publication, and given
the variation in distributions of CMS classes among the
six datasets from which the CMS classification origi-
nated [1–3,5–8], it may be that the CMS class distri-
bution varies per dataset.
In the study dataset, we used large adenomas to sam-
ple fresh frozen material for research purposes, as well
as routine tissue processing for diagnostics. Therefore,
the majority (95%) of the adenomas were> 1 cm. Given
the association of adenoma size with progression risk
[49], the proportion of CMS3 could be even higher in
smaller adenomas. The current study, however, does not
allow conclusions to be drawn about the stage of devel-
opment from normal epithelium to adenoma at which a
CMS signature becomes detectable.
The present study focused on conventional adeno-
mas, which are the most common precursors of CRC,
especially in the context of CIN [50], representing the
classic adenoma-to-carcinoma progression model. More
recently, a serrated pathway has been introduced, with
sessile serrated lesions being precursors of CRC [50].
The CMS classification of these lesions has already
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been presented besides the CMS classification of a small
number of tubular adenomas, and resulted in a different
distribution of the CMS classes from that observed in the
current study [51]. However, given the highly selective
composition of adenomas in this dataset and its con-
siderable differences from our study cohort, significant
variation in CMS classification is to be expected.
Technically, a combined analysis of the study dataset
and the TCGA CRC series was performed to reduce
the effect of the RNA-seq data normalisation on the
CMS classification. Additionally, because of a further
normalisation step implemented in the random forest
CMS algorithm, combined analysis reduced the impact
of the potentially different distribution of CMS classes
in the study dataset from that in the original CMS
training set. The concept of batch effect adjustment to
a ‘gold-standard’ dataset, which the model was trained
on, and classification by use of a merged dataset was
previously introduced [26]. This approach proved to
be appropriate for our research question by providing
stability to the classifier in comparison with applying it
on the study dataset alone (data not shown). The CMS
classification of TCGA data performed in this study was
not biased by our approach, as the original CMS labels
for these samples were reassigned with an accuracy of
97%. Additionally, the CMS classification results for the
adenomas were largely reproduced with the SSP CMS
classifier (supplementary material, Tables S9 and S10).
The SSP method is not sensitive to the composition of
the dataset on which it is applied, so it did not require the
context of a large series of CRCs or batch effect removal.
Therefore, it is suitable for validation of the entire data
analysis approach. The SSP method confirmed the CMS
classes of adenomas to a large extent; however, in some
cases, it lacked confidence in recognising CMS1 or
CMS2 expression traits.
So far, classification of colorectal neoplasia has been
morphology-based. Adenomas are classified on the
basis of histological type, size and grade of dysplasia,
whereas cancers are subtyped on the basis of grade of
differentiation and stage. The CMS classification is an
approach for molecular classification of cancers based
on RNA expression. The present study has extended this
approach to colorectal adenomas, and has demonstrated
that CMS classification can be effectively applied
to these lesions. In conclusion, colorectal adenomas
proved to be heterogeneous in terms of CMS class, but
with a different distribution from that of cancers. CMS3
turned out to be the most prevalent among the conven-
tional adenomas, and our results indicate that it may
represent mostly adenomas at low risk of progressing to
CRC as compared with CMS1 or CMS2 adenomas. The
frequency of CMS classes observed in adenomas is con-
sistent with what could be expected on the basis of dif-
ferences between adenomas and carcinomas, and on the
proportion of adenomas expected to progress to cancer.
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